Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

Fig. 2

OS/PFS Analyses By LDH and Pre-Treatment Disease Burden. a and b Kaplan-Meier plots of progression free survival after HD IL-2 therapy in melanoma patients compared by extent of pre-treatment LDH levels (a) and site of metastatic disease (b). c and d Kaplan-Meier plots of overall survival after HD IL-2 therapy in patients compared by pre-treatment LDH levels (c) and site of metastatic disease (d). All p-values significant and unadjusted for multiple comparisons

Back to article page